Ambulance handover delays unacceptable
Ambulance crews in a single week faced more than 1,800 hours of delays in handing over patients to a hospital trust's A&E departments, according to a report.
The figures from February emerged at a board meeting of the NHS trust that runs Royal Stoke and Stafford's County hospitals, and were branded "unacceptable" by chief executive Simon Constable.
The board of University Hospitals of North Midlands (UHNM) also heard that during another week last month, ambulance patients faced an average handover time of more than two hours.
Members heard the trust had continued to face challenging winter conditions since critical incidents were declared in December and January.
Mr Constable, at the latest board meeting on Wednesday, said there had been "a really difficult few weeks".
He said: "As we went into winter there has been problem after problem ever since."
Factors that "dented" resilience included infectious diseases including flu, Covid, RSV and norovirus.
He said: "While there are external factors, there are a lot of things we need to fix from an internal point of view."
Ambulance holds – or handover delays – saw 1,729 hours lost in the week commencing 27 January and 1,806 hours lost in the week commencing 24 February, he said.
That figure fell to 936 hours lost in the week commencing 3 March, the meeting heard.
Mr Constable said: "There has been a significant improvement. That's the best figure we have had since December. But that is still unacceptable."
The trust has brought in an urgent and emergency care recovery director to help improve performance and there is an improvement plan in place.
Actions have included standing down non-urgent elective work where possible to increase capacity.
Outpatient appointments were also stood down to allow emergency department teams to provide support, board papers said.
Work is taking place to increase the number of patient discharges to free up bedspace, and an extra 50 beds have opened at community hospitals.
This news was gathered by the Local Democracy Reporting Service, which covers councils and other public service organisations.
Follow BBC Stoke & Staffordshire on BBC Sounds, Facebook, X and Instagram.
Hospital bosses apologise after ambulance delays
University Hospitals of North Midlands NHS Trust

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Epoch Times
43 minutes ago
- Epoch Times
Wisconsin Breaks From CDC, Keeps COVID-19 Vaccine Recommendation for Pregnant Women
Wisconsin's health department is keeping in place its recommendation that pregnant women and all children receive one of the currently available COVID-19 vaccines, diverging from guidance by the Centers for Disease Control and Prevention. The Wisconsin Department of Health Services
Yahoo
44 minutes ago
- Yahoo
Multi-Blood Monitoring System Market is expected to reach USD 3.9 billion by 2034, with a 6.4% CAGR growth
Multi Blood Monitoring System Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- The global multi blood monitoring system market is witnessing dynamic expansion, with its value estimated at approximately USD 2.1 billion in 2024, and expected to grow to around USD 3.9 billion by 2034. This translates into a Compound Annual Growth Rate (CAGR) of 6.4% over the forecast period from 2025 to 2034. This growth is primarily fueled by the increasing demand for accurate, efficient, and accessible blood monitoring technologies across various healthcare applications. Download PDF Brochure: These devices are critical in the management of chronic diseases such as diabetes and cardiovascular conditions. As the global burden of such illnesses escalates, particularly among aging populations and across developing regions, the need for real-time, portable, and user-friendly blood monitoring systems has become more urgent than ever. Market Drivers and Opportunities Several underlying factors are contributing to the expansion of this market. Among the most significant drivers is the rising prevalence of chronic diseases. The World Health Organization (WHO) forecasts that by 2030, chronic diseases will account for over 75% of global deaths, highlighting the growing necessity for continuous and reliable health monitoring tools. Moreover, technological advancements in wearable devices, mobile health apps, and telemedicine have revolutionized the way blood monitoring is conducted. These innovations have led to more personalized and preventive healthcare solutions, allowing patients to self-monitor in real-time, often without the need for clinical supervision. This trend is particularly appealing to tech-savvy consumers and younger demographics who are increasingly proactive about their health. Emerging economies also present significant growth potential. With rising healthcare expenditure, expanding middle-class populations, and improving medical infrastructure, regions such as Asia-Pacific, Latin America, and parts of the Middle East are becoming fertile grounds for market expansion. Additionally, the integration of AI and machine learning into monitoring systems is creating opportunities for predictive diagnostics and tailored treatment strategies, revolutionizing the future of personalized medicine. Key Market Challenges Despite its positive growth outlook, the multi blood monitoring system market faces certain challenges. One of the primary obstacles is the complex regulatory landscape. Medical device manufacturers must navigate stringent approval processes, especially in developed regions like North America and Europe. These regulations, although necessary for ensuring safety and efficacy, often delay product rollouts and increase development costs. Supply chain disruptions have also impacted the market, particularly during and after the COVID-19 pandemic. Delays in procuring raw materials, component shortages, and transportation hurdles have affected production timelines and product availability. Furthermore, high costs associated with technologically advanced blood monitoring devices can be a deterrent for adoption, especially in price-sensitive markets. Healthcare providers are often pressured to deliver cost-effective solutions, which can limit investments in premium monitoring systems. Another pressing concern is data security and patient privacy. With the growing digitalization of healthcare and increased reliance on cloud-based data storage, ensuring the protection of sensitive patient information has become paramount. Regulatory frameworks such as HIPAA and GDPR are placing additional burdens on companies to fortify their cybersecurity measures. Market Segmentation Analysis By Product Type The market is segmented into several product categories including continuous glucose monitoring (CGM) systems, blood pressure monitors, cholesterol testing devices, and complete blood count (CBC) test devices. Among these, CGM systems are emerging as the dominant product category, accounting for roughly 35% of market share. The increased prevalence of diabetes globally has significantly contributed to this trend. Blood pressure monitoring devices come in second, capturing an estimated 25% of the market, owing to the widespread incidence of hypertension. Cholesterol testing devices follow with a 15% market share, as more individuals become aware of the risks associated with high cholesterol levels. By End User Hospitals are the largest consumers of multi blood monitoring systems, accounting for nearly 45% of the market share. The growing number of patients and a strong focus on preventive healthcare are driving demand in this segment. Diagnostic laboratories represent the second-largest user group, contributing 30% of market revenue, largely due to the complexity and volume of testing they handle. Homecare settings have gained traction, especially post-pandemic, and currently hold around 20% of the market. The convenience of remote monitoring has been widely appreciated, particularly among the elderly and chronically ill patients who prefer in-home testing. By Technology From a technology standpoint, wearable technologies are transforming the landscape, projected to represent 40% of the market by 2034. These devices offer unmatched convenience and user engagement. Invasive technologies still maintain a solid 45% market share, particularly in clinical environments where precision is critical. Meanwhile, non-invasive technologies are growing steadily and are expected to hold 15% of the market, driven by advancements in optical and sensor-based innovations. By Application Diabetes management remains the top application area, constituting about 50% of the total market. As diabetes rates continue to climb worldwide, the demand for continuous and accurate glucose monitoring devices is increasing proportionally. Cardiovascular monitoring is another important application, making up 30% of the market, while fitness and wellness monitoring is growing rapidly, accounting for around 15% as consumers adopt proactive health strategies. By Distribution Channel In terms of distribution, offline sales still dominate with a 55% market share, primarily due to the preference for in-person consultations and product demonstrations in hospital and clinical settings. Online channels, however, are growing fast and now represent 30% of sales, fueled by digital adoption and e-commerce growth. Direct sales—through specialized distributors—comprise the remaining 15%, ensuring product customization and support services. Browse full Report - Market Segmentation Product Type - Continuous Glucose Monitoring Systems - Blood Pressure Monitoring Devices - Cholesterol Testing Devices - Complete Blood Count Test Devices - Others End-User - Hospitals - Diagnostic Laboratories - Homecare Settings - Research Institutions Technology - Wearable Technology - Non-invasive Technology - Invasive Technology Application - Diabetes Management - Cardiovascular Monitoring - Blood Disorders Management - Fitness and Wellness Monitoring Distribution Channel - Online Sales - Offline Sales - Direct Sales Region - North America - Europe - Asia Pacific - Latin America - Middle East & Africa Regional Outlook Regionally, North America leads the global market, accounting for approximately 40% of total revenues in 2024. This dominance is attributed to advanced healthcare infrastructure, favorable regulatory support, and the presence of leading industry players. Europe follows with a 30% market share, supported by robust public healthcare systems and a rising focus on personalized medicine. The Asia-Pacific region is the fastest-growing market, projected to expand at a CAGR of 7.5%. This growth is driven by large patient populations, increasing disposable income, and government initiatives to enhance healthcare access. Countries such as China, India, and Japan are key contributors to this growth trajectory. Latin America and the Middle East & Africa collectively account for a modest share (5% in 2024) but are poised for steady growth due to improvements in healthcare infrastructure and expanding awareness about chronic disease management. Key Competitors Abbott Laboratories Roche Holding AG Siemens Healthineers Becton, Dickinson and Company (BD) Medtronic plc Nova Biomedical Johnson & Johnson Dexcom, Inc. Arkray, Inc. Ascensia Diabetes Care Terumo Corporation GlySens Incorporated Insulet Corporation Elysium Health LabCorp Recent Industry Developments Several companies have made notable strides in advancing this market: Abbott Laboratories launched FreeStyle Libre 3, a real-time glucose monitor with a discreet sensor, in June 2023, strengthening its lead in the CGM space. In April 2023, Roche formed a strategic partnership with a wearable tech firm to integrate blood monitoring devices with smart devices, enhancing patient engagement and adherence. Siemens Healthineers acquired an AI-based diagnostics company in August 2023, signaling a deeper focus on precision diagnostics through data analytics. Dexcom received FDA approval in September 2023 for a no-fingerstick CGM device, which is likely to broaden its user base and redefine market standards. Medtronic expanded its product line into Asia and Africa in July 2023, targeting underserved markets and accelerating growth in emerging economies. This report is also available in the following languages : Japanese (マルチ血液モニタリングシステム市場), Korean (다혈액 모니터링 시스템 시장), Chinese (多血液监测系统市场), French (Marché des systèmes de surveillance sanguine multi-sang), German (Markt für Multi-Blutüberwachungssysteme), and Italian (Mercato dei sistemi di monitoraggio multi-sangue), etc. Request Sample Pages: More Research Finding – Medical Refrigerated Market The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034. Cardiovascular Monitoring Devices Market The cardiovascular monitoring devices market is valued at approximately $10.5 billion in 2024, with projections indicating substantial growth, reaching around $16.8 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 4.8% during the forecast period from 2025 to 2034. Non Invasive Hemodynamic Detection System Market The global Non-Invasive Hemodynamic Detection System market is valued at approximately USD 2.1 billion in 2024, with strong growth anticipated over the next decade. By 2034, the market is projected to reach around USD 4.5 billion, representing a Compound Annual Growth Rate (CAGR) of approximately 8.0%. Disposable Syringes and Accessories Market The global disposable syringes and accessories market is valued at approximately $7.5 billion in 2024, with a projected growth trajectory that anticipates reaching around $13 billion by 2034. This translates to a compound annual growth rate (CAGR) of about 6.1% over the 2025-2034 period. Blood Collection Mixer Market The blood collection mixer market is valued at approximately $250 million in 2024 and is projected to reach around $400 million by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of about 5.1% during the forecast period from 2025 to 2034. Hemochromatosis Treatment Market The global hemochromatosis treatment market is valued at approximately $2.1 billion in 2024. The market is anticipated to grow significantly, reaching an estimated $3.5 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period of 2025–2034. Gestational Trophoblastic Disease Market The gestational trophoblastic disease (GTD) market is currently valued at approximately $1.8 billion in 2024, with projections indicating a potential growth to around $3.1 billion by 2034. This represents a compound annual growth rate (CAGR) of approximately 6.2% during the forecast period from 2025 to 2034. Septicemia Diagnostic Market The global septicemia diagnostics market is valued at approximately $1.5 billion in 2024, with projections indicating a growth to around $2.9 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 7.5% for the period from 2025 to 2034. Single Use Safety Lancet Market The global market for single-use safety lancets, valued at approximately $1.2 billion in 2024, is expected to reach around $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period from 2025 to 2034. Microalbuminuria Test Strip Market The microalbuminuria test strip market is poised for notable growth, valued at approximately $1.2 billion in 2024. This market is projected to expand to around $2.4 billion by 2034, indicating a robust growth trajectory. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 7.3%. Monkeypox Virus Detection Reagent Market The monkeypox virus detection reagent market is anticipated to reach approximately $150 million in value by 2024, driven by heightened awareness and diagnostic needs amid ongoing public health surveillance. The market is projected to expand significantly, reaching an estimated $300 million by 2034, reflecting sustained interest in infectious disease diagnostics and preparedness. Blood Tester Market The global blood testing market is anticipated to reach a value of approximately $75 billion in 2024, driven by increasing prevalence of chronic diseases, rising health awareness, and advancements in diagnostic technologies. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2025 to 2034, potentially reaching over $135 billion by 2034. HBsAg ELISA Test Kit Market The HBsAg ELISA Test Kit market is poised for robust growth, with a current market value estimated at approximately $1.5 billion in 2024. Driven by the increasing global prevalence of Hepatitis B, ongoing advancements in diagnostic technologies, and rising healthcare expenditures, the market is projected to reach around $2.8 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 6.5% from 2025 to 2034. Blood Plasma Extractor Market The global blood plasma extractor market is valued at approximately $1.2 billion, driven by rising demand for plasma-derived therapies in treating various diseases. The market is projected to reach about $2.9 billion by 2034, reflecting an impressive Compound Annual Growth Rate (CAGR) of approximately 9.2% from 2025 to 2034. Amphetamine Test Kit Market The amphetamine test kit market is projected to reach a value of approximately $500 million in 2024, with expectations to grow to around $900 million by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 6% during the forecast period of 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors, today announced that clinical data for its next-generation COVID-19 multi-antigen vaccine candidate, GEO-CM04S1, will be presented at the European Hematology Association (EHA) 2025 Hybrid Congress, taking place June 1215, 2025, in Milan, Italy and online. Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center in Duarte, California, will present a poster titled: "MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study". The poster will be featured on Saturday, June 14, 2025, from 18:30 to 18:30 CEST in the Poster Hall, as part of the session on Infections in Hematology (including supportive care/therapy). The presentation will highlight initial results from a Phase II randomized clinical trial highlighting the superior cellular immune response of GEO-CM04S1 compared to an authorized mRNA-based COVID-19 vaccine in CLL patients - a population known to exhibit suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction. The findings will underscore the differentiated mechanism and clinical potential of the GeoVax MVA multi-antigen platform, particularly in immunocompromised individuals. "GEO-CM04S1 continues to show promise as a vaccine option for populations with suboptimal protection from existing COVID-19 vaccines," said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. "We are proud to have these important data showcased at EHA2025, reflecting the real-world needs of patients with hematologic malignancies." About GEO-CM04S1 GEO-CM04S1 is a multi-antigen COVID-19 vaccine designed using a synthetic Modified Vaccinia Ankara (MVA) vector platform. The vaccine expresses both spike (S) and nucleocapsid (N) antigens of SARS-CoV-2, aiming to provide broader and more durable immune protection. It is currently being evaluated in Phase 2 clinical trials in both immunocompromised and healthy adults. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relations Contact:geovax@ Sign in to access your portfolio